Setback after earlier optimism: the Roche drug giredestrant has delivered mixed clinical data. Several clinical trials had suggested the drug could play an important role in the treatment of hormone-dependent breast tumours and potentially become a blockbuster for the company. Now, however, a key Phase III study has failed to meet its primary endpoint, even as regulatory submissions are already under way.
New CFO with Novartis experience
AppointmentsIn March, Mukul Mehta took over as the new Chief Financial Officer at Basel-based Biotech and Pharma Company Novartis. At the same time, he became a member of the Executive Committee.
Ternary Therapeutics lands €4.1M seed round to push AI-designed molecular glues into inflammatory disease
Latest NewsLondon-based Ternary Therapeutics has raised a €4.1 million seed round to expand its platform for designing molecular glue drugs, with Paris-based VC daphni leading the financing alongside Pace Ventures, i&i Biotech Fund and Future Planet Capital.
3PBIOVIAN and INC partner to expand access to oncology treatments in Colombia through biosimilar development
Sponsored Publications3PBIOVIAN consolidates its position as a trusted partner for the development and manufacturing of complex biological products, combining scientific excellence, regulatory expertise, and strong social commitment.
Owkin spins out AI diagnostics startup Waiv with $33M financing
Latest NewsFrench AI biotech Owkin has spun out its diagnostics division as a new company, Waiv, raising $33 million in financing led by OTB Ventures and Alpha Intelligence Capital to scale AI-powered precision testing.
Vienna’s VALANX secures €3 million to push preclinical ADC programme in breast cancer
Latest NewsVALANX Biotech has raised €3 million in a Series A funding round to advance an antibody-drug conjugate (ADC) targeting LIV-1 for triple-negative breast cancer. The developments are currently still at the preclinical stage.
Enodia strikes up to $127m deal for Kezar’s preclinical protein degradation assets
Latest NewsParis-based Enodia Therapeutics announced the acquisition of preclinical assets from San Francisco-based Kezar Life Sciences’ pipeline. Both companies are developers of small molecules that target protein degradation, a field that is attracting significant attention for its potential to treat previously intractable diseases.
Hamburg CRO Evotec to cut costs further and reduce workforce by 800
Latest NewsCost-cutting measures sometimes arrive wrapped in reassuring language. “Horizon” is the name Evotec SE has given to the next stage of its restructuring programme, which will affect additional sites and their employees. Up to 800 staff may find it difficult to look past the polished wording.
Ipsen withdraws cancer drug following safety concerns
Latest NewsIpsen has announced the immediate withdrawal of its cancer drug Tazverik across all indications after serious safety issues emerged in an ongoing Phase III trial.
A new departure: BioNTech’s founders step aside – Sahin and Türeci in new venture
Latest NewsThe Mainz-based biotech company BioNTech is facing a historic leadership change as the minds behind the COVID-19 vaccine prepare for a fresh start. Uğur Şahin and Özlem Türeci plan to focus entirely on mRNA platform technology and will launch a spin-off at the end of the year.
Roche breast cancer drug falls short of expectations (for now)
Latest NewsSetback after earlier optimism: the Roche drug giredestrant has delivered mixed clinical data. Several clinical trials had suggested the drug could play an important role in the treatment of hormone-dependent breast tumours and potentially become a blockbuster for the company. Now, however, a key Phase III study has failed to meet its primary endpoint, even as regulatory submissions are already under way.